RESULTS. More than 300 articles relating to SCC in OTRs were reviewed. In general, reports concerning the prevention and treatment of SCC in OTRs are of individual cases or small case series. They are retrospective in nature, statistically nonrigorous, and lack the complete epidemiologic data necessary to derive definitive conclusions. Combining these studies and collective clinical experience, however, is at present the best available method for devising guidelines for the treatment of SCC in OTRs. CONCLUSION. Guidelines developed for the treatment of skin cancer in OTRs, supported by the best available data and collective clinical experience, may assist in the management of OTRs with SCC. The development of clinical pathways and complete documentation with rigorous prospective study is necessary to improve and refine future guideline development. 1. To integrate and support basic scientific and clinical research to address the special needs of solid-organ transplant recipients with skin cancer to improve quality of care. 2. To educate patients, scientists, primary care doctors, and specialist physicians on the unique needs and clinical care issues in solid-organ transplant patients.
The European Skin Care in Organ Transplant Recipients (SCOP) Network was developed with similar goals. The SCOP Network began in December 2000 with national organizations in France, Italy, and Germany and was expanded to a European level in June 2002. In addition, SCOP is developing an Internet-based data registry uniting multiple specialized dermatologic outpatient departments from all parts of Europe. This database will allow the collection of comprehensive epidemiologic data on skin diseases in organ transplants. The data gathered will be used to reevaluate existing strategies of skin cancer prevention as well as to develop new therapeutic options for cancerous and infectious skin diseases.
Background
Fair-skinned organ transplant recipients (OTRs) develop cutaneous malignancies at rates that have been estimated to be up to 100 times that of the general population. [1] [2] [3] In Norway there is required reporting of all cutaneous malignancies, with the exception of basal cell carcinoma. As a result an accurate general prevalence of nonmelanoma skin cancer (NMSC) in the population is known. Against this background a study of a cohort of kidney and cardiac transplant patients from a single Norwegian center found the rate of squamous cell carcinoma (SCC) to be 65 times that the general population when controlled for age and sex. The risk for melanoma increased 3-fold, Kaposi's sarcoma 84-fold, and SCC of the lip 20-fold. 4 Merkel cell carcinoma also appears to be more frequent and aggressive in transplant recipients. 5 Skin cancers also develop at a younger age in OTRs, often starting 3 to 5 years after transplantation. 6, 7 Those OTRs who do develop skin cancers often develop multiple tumors. In a study from Queensland, Australia, the average number of tumors was 7.5 per patient with a standard deviation of 17.5 and 76% of the patients who had a skin cancer before transplantation developed additional tumors with an average of 16.5 tumors per individual. 8 Nonmelanoma skin cancers in OTRs can be very aggressive. Data from the Cincinnati Tumor Registry indicated that 5.2% of all transplant patients died of skin malignancies with 63% of those deaths coming from SCC. 9 In a group of Australian heart transplant recipients, skin cancer caused 27% of the 41 deaths, which occurred 4 or more years after transplantation. 10 Guidelines for care of NMSC in the general population have been previously published by the National Comprehensive Cancer Network 11 and the American Academy of Dermatology. 12 Guidelines for the prevention and treatment of skin cancers in renal transplant patients have been recently published, but are somewhat general in nature. 13 There are no largescale, long-term studies available that address the care of SCC in OTRs. The goal of the Guidelines Committee of the ITSCC is to develop guidelines for the treatment of skin cancer in OTRs, supported by the best available data and collective clinical experience, to assist in the management of these patients. The development of clinical pathways and complete documentation may also be useful for development of prospective database trials for future guideline revisions.
Screening and Education
Patients should receive a skin cancer-oriented history and physical before transplantation if practical. All patients should be given education regarding sun exposure and the recognition of premalignant and malignant skin lesions in high-risk patients should be identified for closer follow-up. The initial skin exam should include a detailed history with an emphasis on skin cancer, sun exposure, and warts and a family history of skin cancer. All OTRs are considered to be at increased risk for the development of skin cancer; however, several factors indicate a higher degree of susceptibility within this group. These factors include:
1. History of skin cancer. 9 2. History of actinic keratoses. 5. Older age. [17] [18] [19] [20] 6. Duration and intensity of immunosuppression. 17, [20] [21] [22] 7. History of human papillomavirus infection. 23, 24 8. CD4 lymphocytopenia. 25 The patient should be examined for the presence of actinic damage, human papillomavirus infection, premalignant lesions, and skin malignancies (Figure 1 ).
OTRs should receive extensive education about the risk of developing skin cancer and its associated morbidity and mortality. They should be educated concerning sun protection including avoidance of sun exposure, the wearing of protective clothing and the use of effective UVB/UVA sunscreens with an effectively high sun protection factor (15 or higher in the United States) to all sun exposed areas on a daily basis. [26] [27] [28] Tanning bed use should be prohibited. It is unknown whether the use of other prophylactic measures (topical retinoids, topical 5-fluorouracil, chemical peel, etc.) before the development of precancerous and cancerous lesions will retard their development. Education should be repeated at regular intervals to maintain its effectiveness. [29] [30] [31] Owing to the high prevalence and associated morbidity and mortality of skin cancer in OTRs, patients should receive education before transplantation regarding the risk of developing skin cancer. To enhance early detection and treatment OTRs should be educated in the clinical appearance of common benign, premalignant, and malignant neoplastic skin lesions. OTRs should be taught self-examination of the skin for early detection of malignant and premalignant lesions. Each OTR should then be examined at appropriate time intervals determined by the individual's risk for skin cancer development (see Tables 1 and 2 ).
Evaluation and Management of Warts and Premalignant Lesions
Warts, actinic keratoses, and porokeratoses should be treated aggressively at first development. Prophylactic use of topical retinoid derivatives may decrease the development of additional premalignant lesions.
32 Adjusting immunosuppression to the lowest level consistent with safely maintaining graft function may also decrease the development of premalignant skin lesions. Adjustment of immunosuppressive medications should only be done in consultation with the patient's primary transplant physician.
Warts, actinic keratoses, and porokeratoses that have an atypical clinical appearance or do not respond to appropriate therapy should be biopsied for histologic evaluation.
It may be difficult to distinguish SCC from warts and premalignant lesions on a clinical basis. 33 Review of systems exam (i.e., constitutional, lungs). Full-body skin exam including scalp, genitalia, and feet at least annually. Regional sun-exposed skin exam at other visits. Reevaluation of previous sites of NMSC, including regional lymph node exam with attention to the primary drainage basin(s). Treat actinic keratoses early. Low threshold for skin biopsy-full-thickness biopsy is recommended for definitive diagnosis and histologic evaluation. Laboratory and radiologic studies are reserved for patients with signs and symptoms of metastatic disease. Patient education with regard to sun exposure and selfexamination of the skin and lymph nodes should be given.
Abbreviations: NMSC, nonmelanoma skin cancer.
Evaluation and Management of SCC
All OTRs with suspected or proven SCC should have a thorough pretreatment evaluation.
Evaluation with notation in the medical record is vitally needed for future study analyses and should include:
1. History of the lesion including duration, rate of growth, prior treatment, and associated pain or tenderness. 2. The size and site of the lesion. Less aggressive SCC in OTRs should be promptly managed with techniques including, but not limited to, destructive modalities and excisional techniques ( Figure 2 ). Histology should be obtained on all lesions. < 0.6 cm, "mask" areas of the face (central face, eyelids, eyebrows, periorbital, nose, lips, chin, mandible, preauricular and postauricular areas, temple, and ear), genitalia, hands, and feet <1.0 cm, cheeks, forehead, neck, and scalp <2.0 cm, trunk and extremities **Location NOT on scalp, ear, lip, midface, genitalia, or nail unit or within an anatomic fusion plane ***See Table 2 Well differentiated Biopsy for histologic exam should be performed before or at the time of treatment. If performed at the time of treatment histologic material should be reviewed to assure that the lesion has characteristics of less aggressive SCC. Tangential excision for histology followed by one of the destructive modalities may be employed. Because OTRs may develop multiple lesions over relatively short periods of time, destructive modalities may be preferred in less aggressive SCC because of the ability to treat multiple lesions at a single setting.
Destructive techniques for treatment of less aggressive SCC in OTRs include:
Electrodesiccation and curettage (ED&C). ED&C
has been shown to be effective in the treatment of selected cutaneous SCC. 35 Not surprisingly, successful outcome correlated with physician experience in the treatment of basal cell carcinoma. 36 Based on the higher potential rate of recurrence after ED&C, 37 it is suggested that this method may be less effective for SCC located on the high risk area of the head and neck of OTRs. 2. Cryosurgery to -501C has been shown to be effective treatment for selected SCC. 38 Combinations of curettage with cryosurgery have also been utilized. Aggressive SCC still confined to the skin and soft tissue in OTRs should be managed promptly with complete removal with excisional techniques (Figure 3 ). Additional modalities may be helpful in some situations.
Characteristics of SCCs at risk for invasive growth, recurrence, or metastasis in OTRs include: > 0.6 cm, "mask" areas of the face (central face, eyelids, eyebrows, periorbital, nose, lips, chin, mandible, preauricular and postauricular areas, temple, and ear), genitalia, hands, and feet >1.0 cm, cheeks, forehead, neck, and scalp >2.0 cm, trunk and extremities **Location on scalp, ear, lip, midface, genitalia, or nail unit or within an anatomic fusion plane ***Or excision with margin control or primary radiation therapy in select situations ****See Table 2 Clear Excisional modalities for the treatment of aggressive SCC in OTRs include:
1. Mohs micrographic surgery offers the highest cure rates and optimal conservation of normal tissue in selected NMSC including SCC. 37, 39, 40 Local control rates achieved with Mohs surgery are very high in primary SCC, recurrent SCC, and high-risk SCC. 2. Excision with intraoperative frozen section control may also result in high cure rates when performed by a surgeon and pathologist with expertise and experience in the procedure. 3. Excision with postoperative margin assessment may be considered if Mohs micrographic surgery or excision with intraoperative frozen section control is not available, if the lesion is of such a size that complete intraoperative margin evaluation is not practical, if the lesion is of such a size or depth that excision under local anesthesia is not feasible, if the patient has significant comorbidities requiring monitored anesthesia, or if tissue conservation is not an issue. Margins of at least 6 to 10 mm beyond any surrounding erythema and resection into the subcutaneous fat are recommended. 37 Frozen section analysis of selected margins may be useful. Additional modalities include:
1. Radiation therapy can be considered as a primary modality for inoperable tumors and in patients unable to tolerate surgical excision. 43 Although radiation therapy can be a valuable primary modality for selected tumors, the primary difficulties in OTRs lie in the lack of margin control and the tendency of OTRs to develop multiple, often adjacent tumors. Adjunctive radiation treatment should be considered in the following circumstances:
a. Inability to achieve margins clear of invasive tumor by surgery; b. Presence of substantial perineural invasion/inflammation. [44] [45] [46] [47] [48] 2. Sentinel lymph node biopsy (SLNB) is not currently used routinely in the evaluation of high risk SCC. Recent small studies, however, are beginning to support a potential role for SLNB in evaluation of high risk NMSC. In one study, 49 20 patients with T2 (size 4 2 cm) SCCs on the lower lip underwent SLNB with the sentinel node identified in 18 (90%). Nodal disease was identified in 3 of these patients (18.8%). The role of SLNB in evaluation of higher risk SCCs in OTRs remains to be completely defined. SLNB may be considered in cases higher risk SCC, but usually should be reserved for clinical research settings and selected situations at centers with expertise and experience in SLNB. 3. Chemoprophylaxis with oral retinoids (acetretin, etretinate, isotretinoin) has been effective in reducing the development of skin cancers and premalignant lesions in OTRs with multiple skin lesions. [50] [51] [52] [53] The effect is not absolute and some tumors continue to develop during therapy. The effect is not durable after cessation of the drug. When the retinoid is discontinued, a rebound is almost always noted with the rate of new lesion formation matching or exceeding the pretreatment rate. Many patients are unable to tolerate the side effects of oral retinoids on a long-term basis. Blood chemistries including liver function studies and lipid levels must be monitored. The teratogenicity of oral retinoids dictates that extreme caution is necessary when these drugs are administered to women of childbearing potential. There are no long-term safety studies of the use of oral retinoids in OTRs. 4. Excision and split-thickness skin grafting of the dorsa of the hand and forearm has been utilized for the treatment of multiple SCC of these areas with good results. The grafted area remains tumor-free for an extended period of time. The procedure has significant morbidity and entails a significant recovery period. [54] [55] [56] 5. Decreasing immunosuppression should be considered in cases of life-threatening skin cancers in OTRs and the rapid development of multiple SCCs in OTRs. There are reports of decreased internal cancers with low-dose rather than high-dose cyclosporine 22 as well as decreased skin cancers in a small series of patients in whom immunosuppressive medications were discontinued. 57 Certain organ grafts may survive gradual and complete weaning of immunosuppression, presumably through population of the host with immunosuppressive T cells originating from the graft. 42, [58] [59] [60] The decision to reduce immunosuppression must be made in consultation with the patient's transplant physician.
Satellite lesions (in-transit cutaneous metastases) of SCC in OTRs require additional therapy and evaluation (Figure 4 ). With all evaluation, prevention, and treatment strategies, a collaborative approach between transplant physicians, dermatologists, oncologic surgeons, pathologists, medical oncologists, and radiation oncologists with experience with aggressive tumors in OTRs is optimal. 63 
Summary
The increased incidence of SCC in OTRs is a major cause of morbidity and mortality in a select group of patients. Unfortunately, there are few prospective, controlled studies concerning the prevention and treatment of SCC in OTRs and limited observational studies have been published. Theses guidelines are based on the best currently available data and the experience of the authors and other members of ITSCC. The guidelines are designed to provide guidance and not prescribe treatment for individual patients. Hopefully, they will stimulate further study of this problem. The guidelines will require continuous modification as additional, more rigorous studies and experience become available. 
